United Therapeutics Corporation announced on May 23, 2022, the FDA approval of the oral form of Treprostinil (TYVASO DPI), a strategic move to broaden the accessibility and convenience of its pulmonary arterial hypertension therapies while enhancing market competitiveness against oral competitors. This expansion of the Treprostinil portfolio is expected to increase the company's addressable patient base and drive further revenue growth within the chronic pulmonary hypertension sector.